Table 6

Relapse-free and overall survival with respect to biomarker score for test and validation sets

Survival

Division

Test set

Validation set

n

Median RFS, years (95% CI)

10-year RFS, percentage (SEM)

n

Median RFS, years (95% CI)

10 year RFS, percentage (SEM)

RFS

Overall cohort

313

5.2 (3.9–6.5)

38.3 (2.9)

289

5.8 (4.4–7.3)

38.1 (2.9)

0

38/227

NR

75.4 (7.1)

40/219

9.7 (5.5–14.0)

47.8 (8.4)

1–4

154/227

4.8 (3.6–6.1)

35.3 (4.1)

146/219

5.8 (3.9–7.7)

37.8 (4.2)

5–8

35/227

1.6 (0.8–2.3)

19.3 (7.0)

33/219

2.4 (0.9–3.8)

30.3 (8.0)

All markers

227/227

5.2 (3.6–6.9)

39.8 (3.4)

219/219

5.8 (4.2–7.5)

38.5 (3.4)

OS

Overall cohort

313

6.7 (5.7–7.8)

39.5 (3.4)

289

7.3 (5.9–8.6)

39.1 (2.9)

0

38/227

15.5 (10.9–20.1)

67.6 (7.7)

40/219

9.3 (5.5–13.1)

47.5 (7.9)

1–4

154/227

6.4 (5.3–7.5)

35.1 (3.8)

146/219

7.8 (5.8–9.9)

38.4 (4.0)

5–8

35/227

2.7 (1.1–4.3)

21.6 (6.8)

33/219

3.3 (1.7–4.9)

30.3 (8.0)

All markers

227/227

6.6 (5.2–8.0)

38.2 (3.2)

219/219

7.6 (6.0–9.1)

38.8 (3.3)

Relapse-free and overall survival are presented in the test and validation sets for the overall cohorts, for the subsets with expression scores available for all eight biomarkers assessed and with respect to patient subgroups for biomarker scores of 0, 1 to 4, and 5 to 8. RFS, relapse-free survival; OS, overall survival; NR, not reached; CI, confidence interval.

Crabb et al. Breast Cancer Research 2008 10:R6   doi:10.1186/bcr1847